Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

amgen

Home/Tag:amgen
1 06, 2015

Kyprolis may soon be infused once a week

Tags: , , |4 Comments

Kyprolis is a new, FDA approved proteasome inhibitor, similar to Velcade.  Early on, doctors learned that administering Velcade once weekly worked as well as the FDA approved twice weekly dosing.  Now Amgen, new owners of Onyx Pharmaceuticals and Kyprolis, have initiated a large clinical trial to try and prove the same for Kyprolis. Let's face

3 03, 2015

Kyprolis “superior” to Velcade?

Tags: , , , , |18 Comments

There has been a surprising amount of myeloma related news lately; the FDA's approval of panobinostat last week, and now the early release of data apparently showing that Kyprolis helps keep a relapsed patient's myeloma at bay longer than Velcade. My friends at Onyx (now part of Amgen) forwarded me the release announcing the news

27 08, 2014

RESEARCH UPDATE: Kyrpolis and Total Therapy 3

Tags: , , , , , |4 Comments

I have written a number of times about counter-intuitive research results involving progression free survival (PFS) and overall survival (OS).  Here's another key example. I chose not to write about recent data from FOCUS, a key Kyprolis trial.  The drug's manufacturer, Onyx/Amgen, is attempting to garner FDA approval for myeloma patients that have relapsed two

8 10, 2013

Myeloma News and Views: proteasome inhibitors

Tags: , , , , , , , , |7 Comments

Big news in the myeloma world last week.  Onyx, the company that developed and manufactures the newly FDA approved proteasome inhibitor, Kyprolis (carfilzomib), was purchased by Amgen for a whopping 9.7 billion dollars. If you would like details, I ran a press release about it on our sister site, MyelomaNews.com, October 1st: http://www.myelomanews.com/2013/10/looks-like-proposed-sale-of-onyx-to.html I wrote

9 09, 2013

More about Amgen; Black Swan series starts tomorrow

Tags: , , , |7 Comments

Back in August I reported news that the large drug company, Amgen, planned to purchase Onyx Pharmaceuticals.  This was big news for multiple myeloma patients; Onyx developed and distributes Kyprolis (carfilzomib), a newly FDA approved proteasome inhibitor. Here are links back to my original posts: BREAKING NEWS: Amgen to buy Onyx Pharmaceuticals   Onyx/Amgen sale

25 08, 2013

BREAKING NEWS: Amgen to buy Onyx Pharmaceuticals

Tags: , , , , |13 Comments

This is BIG NEWS, especially for a Sunday afternoon: Amgen to Acquire Onyx Pharmaceuticals for $125 per Share in Cash Attractive Addition to Amgen's Leading Oncology Portfolio and Pipeline Kyprolis(R) (carfilzomib) for Injection Is at Early Stages of Launch in Multiple Myeloma; Showing Strong Physician Support Acquisition Expected to Contribute to Growth and Value for

19 11, 2010

FDA Approves New Cancer Bone Drug, Denosumab (Xgeva), For Use In Patients With Solid Tumors – But Not Multiple Myeloma

Tags: , , , , , , , |4 Comments

Hot "off the presses," here is yesterday afternoon's announcement from the FDA as reported by Reuters:FDA OKs Amgen's bone drug in certain cancersNov 18 2010 - By Deena Beasley* Denosumab approved for patients with solid tumors * Not approved for multiple myeloma* Shares rise 1.6 percent LOS ANGELES, Nov 18 (Reuters) - The U.S. Food

12 10, 2010

Amgen Sites New Studies, Claiming Experimental Drug Denosumab Superior To Zometa

Tags: , , , |2 Comments

Here is the introduction to a very long and technical Amgen press release as featured Sunday on PRNewswire.com:Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa®THOUSAND OAKS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced results from two integrated analyses of head-to-head pivotal Phase 3 trials comparing denosumab

9 02, 2010

Denosumab vs Zometa Phase 3 Randomized Study Results Released Monday

Tags: , , , , , , |0 Comments

Here is a new press release from Amgen, the drug company which manufactures Denosumab.  Denosumab is a bisphosphonate type drug, developed to compete with Zometa and Aredia.  Even though this specific study involves prostate cancer patients, I felt it was important to post it on our multiple myeloma site.  Why?  Because the "buzz" and hopeful excitement